Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients

Author： Hasegawa Mayumi  

Publisher： Springer Publishing Company

ISSN： 1567-567X

Source： Journal of Pharmacokinetics and Pharmacodynamics, Vol.38, Iss.6, 2011-12, pp. : 803-832

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 6, Iss. 12, 2017-12 ,pp. : 804-813

John Wiley & Sons Inc

Access to resources Recommend Favorite

Abatacept attains responses in rheumatoid arthritis

By  

Inpharma, Vol. 1, Iss. 1463, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Abatacept takes aim at rheumatoid arthritis

By  

Inpharma, Vol. 1, Iss. 1501, 2005-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 6, 2015-06 ,pp. : 362-371

John Wiley & Sons Inc

Access to resources Recommend Favorite

Abatacept a strong option for rheumatoid arthritis therapy

By  

Inpharma, Vol. 1, Iss. 1663, 2008-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite